Filter

Refine by collections

  • Hormones and Cancer (11)

Refine by date

—
  • Print
  • Save

Search Results

You are looking at 1 - 10 of 11 items for :

  • Hormones and Cancer x
Clear All
Hanna Karhapää Medical Faculty, University of Helsinki, Helsinki, Finland
Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland

Search for other papers by Hanna Karhapää in
Google Scholar
PubMed Close
,
Siru Mäkelä Medical Faculty, University of Helsinki, Helsinki, Finland
Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland

Search for other papers by Siru Mäkelä in
Google Scholar
PubMed Close
,
Hanna Laurén Medical Faculty, University of Helsinki, Helsinki, Finland
Department of Radiology, HUS Medical Imaging Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

Search for other papers by Hanna Laurén in
Google Scholar
PubMed Close
,
Marjut Jaakkola Medical Faculty, University of Helsinki, Helsinki, Finland
Department of Radiology, HUS Medical Imaging Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

Search for other papers by Marjut Jaakkola in
Google Scholar
PubMed Close
,
Camilla Schalin-Jäntti Medical Faculty, University of Helsinki, Helsinki, Finland
Endocrinology, Abdominal Centre, University of Helsinki and HUS, Helsinki, Finland

Search for other papers by Camilla Schalin-Jäntti in
Google Scholar
PubMed Close
, and
Micaela Hernberg Medical Faculty, University of Helsinki, Helsinki, Finland
Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland

Search for other papers by Micaela Hernberg in
Google Scholar
PubMed Close

-cells, and activate T-cells to attack cancer cells. ICIs used to treat metastatic melanoma include anticytotoxic T-lymphocyte-associated protein-4 (CTLA-4) MAB, ipilimumab ( 1 ) and antiprogrammed cell death protein 1 (PD-1) MAbs, nivolumab and pembrolizumab

Article Type:
Research Article
Collections:
Hormones and Cancer
DOI:
https://doi.org/10.1530/EC-21-0562
Volume/Issue:
Volume 11: Issue 2
Open access
Mark J C van Treijen Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
Center for Neuroendocrine Tumors, ENETS Center of Excellence, Netherlands Cancer Institute, University Medical Center Utrecht, Utrecht, The Netherlands

Search for other papers by Mark J C van Treijen in
Google Scholar
PubMed Close
,
Catharina M Korse Center for Neuroendocrine Tumors, ENETS Center of Excellence, Netherlands Cancer Institute, University Medical Center Utrecht, Utrecht, The Netherlands
Department of Clinical Chemistry, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Search for other papers by Catharina M Korse in
Google Scholar
PubMed Close
,
Wieke H Verbeek Center for Neuroendocrine Tumors, ENETS Center of Excellence, Netherlands Cancer Institute, University Medical Center Utrecht, Utrecht, The Netherlands
Department of Gastroenterology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Search for other papers by Wieke H Verbeek in
Google Scholar
PubMed Close
,
Margot E T Tesselaar Center for Neuroendocrine Tumors, ENETS Center of Excellence, Netherlands Cancer Institute, University Medical Center Utrecht, Utrecht, The Netherlands
Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Search for other papers by Margot E T Tesselaar in
Google Scholar
PubMed Close
, and
Gerlof D Valk Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
Center for Neuroendocrine Tumors, ENETS Center of Excellence, Netherlands Cancer Institute, University Medical Center Utrecht, Utrecht, The Netherlands

Search for other papers by Gerlof D Valk in
Google Scholar
PubMed Close

were considered to have PD. Results Of the 182 eligible patients, 132 were enrolled in the study ( Fig. 1 ). Clinical characteristics of the study population are illustrated in Table 1 . A total of 632 samples were collected in 132 patients

Article Type:
Research Article
Collections:
Hormones and Cancer
DOI:
https://doi.org/10.1530/EC-22-0146
Volume/Issue:
Volume 11: Issue 10
Open access
Kazhan Mollazadegan Department of Medical Sciences, Uppsala University, Uppsala, Sweden

Search for other papers by Kazhan Mollazadegan in
Google Scholar
PubMed Close
,
Britt Skogseid Department of Medical Sciences, Uppsala University, Uppsala, Sweden

Search for other papers by Britt Skogseid in
Google Scholar
PubMed Close
,
Johan Botling Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden

Search for other papers by Johan Botling in
Google Scholar
PubMed Close
,
Tobias Åkerström Department of Surgical Sciences, Uppsala University, Uppsala, Sweden

Search for other papers by Tobias Åkerström in
Google Scholar
PubMed Close
,
Barbro Eriksson Department of Medical Sciences, Uppsala University, Uppsala, Sweden

Search for other papers by Barbro Eriksson in
Google Scholar
PubMed Close
,
Staffan Welin Department of Medical Sciences, Uppsala University, Uppsala, Sweden

Search for other papers by Staffan Welin in
Google Scholar
PubMed Close
,
Anders Sundin Department of Surgical Sciences, Uppsala University, Uppsala, Sweden

Search for other papers by Anders Sundin in
Google Scholar
PubMed Close
, and
Joakim Crona Department of Medical Sciences, Uppsala University, Uppsala, Sweden

Search for other papers by Joakim Crona in
Google Scholar
PubMed Close

grading of panNENs ( 3 ), high-grade neoplasms were separated into two categories: well-differentiated (WD) pancreatic neuroendocrine tumor grade 3 (panNET-G3) and poorly differentiated (PD) NEC ( 4 ). PanNET-G3 frequently harbors mutations in MEN1 and

Article Type:
Research Article
Collections:
Hormones and Cancer
DOI:
https://doi.org/10.1530/EC-21-0604
Volume/Issue:
Volume 11: Issue 3
Open access
Hélène Singeisen Department of Internal Medicine, Endocrinology, Cantonal Hospital Thurgau, Münsterlingen, Switzerland

Search for other papers by Hélène Singeisen in
Google Scholar
PubMed Close
,
Mariko Melanie Renzulli Institute of Radiology, Cantonal Hospital Thurgau, Frauenfeld, Switzerland

Search for other papers by Mariko Melanie Renzulli in
Google Scholar
PubMed Close
,
Vojtech Pavlicek Department of Internal Medicine, Endocrinology, Cantonal Hospital Thurgau, Münsterlingen, Switzerland

Search for other papers by Vojtech Pavlicek in
Google Scholar
PubMed Close
,
Pascal Probst Department of Surgery, Cantonal Hospital Thurgau, Frauenfeld, Switzerland

Search for other papers by Pascal Probst in
Google Scholar
PubMed Close
,
Fabian Hauswirth Department of Surgery, Cantonal Hospital Thurgau, Münsterlingen, Switzerland

Search for other papers by Fabian Hauswirth in
Google Scholar
PubMed Close
,
Markus K Muller Department of Surgery, Cantonal Hospital Thurgau, Frauenfeld, Switzerland

Search for other papers by Markus K Muller in
Google Scholar
PubMed Close
,
Magdalene Adamczyk Department of Pathology and Molecular Pathology, University Hospital Zurich and University of Zurich, Zurich, Switzerland

Search for other papers by Magdalene Adamczyk in
Google Scholar
PubMed Close
,
Achim Weber Department of Pathology and Molecular Pathology, University Hospital Zurich and University of Zurich, Zurich, Switzerland

Search for other papers by Achim Weber in
Google Scholar
PubMed Close
,
Reto Martin Kaderli Department of Visceral Surgery and Medicine, Bern University Hospital, University of Bern, Bern, Switzerland

Search for other papers by Reto Martin Kaderli in
Google Scholar
PubMed Close
, and
Pietro Renzulli Department of Surgery, Cantonal Hospital Thurgau, Münsterlingen, Switzerland

Search for other papers by Pietro Renzulli in
Google Scholar
PubMed Close

Introduction Multiple endocrine neoplasia (MEN) is a rare group of autosomal dominant disorders with a wide spectrum of endocrine and non-endocrine manifestations ( Table 1 ). Five different types of MEN have been described so far: MEN1, MEN2

Article Type:
Research Article
Collections:
Hormones and Cancer
DOI:
https://doi.org/10.1530/EC-22-0411
Volume/Issue:
Volume 12: Issue 2
Open access
Ruth Percik Institute of Endocrinology, Diabetes and Metabolism, Sheba Medical Centre, Ramat Gan, Israel

Search for other papers by Ruth Percik in
Google Scholar
PubMed Close
,
Sherwin Criseno Department of Endocrinology, University Hospital Birmingham, Birmingham, UK

Search for other papers by Sherwin Criseno in
Google Scholar
PubMed Close
,
Safwaan Adam Department of Endocrinology, The Christie NHS Foundation Trust, Manchester, UK

Search for other papers by Safwaan Adam in
Google Scholar
PubMed Close
,
Kate Young Royal Marsden Hospital, London, UK

Search for other papers by Kate Young in
Google Scholar
PubMed Close
, and
Daniel L Morganstein Department of Endocrinology, Chelsea and Westminster Hospital, London, UK
Royal Marsden Hospital, London, UK

Search for other papers by Daniel L Morganstein in
Google Scholar
PubMed Close

used to describe the resultant long-term deficiencies of at least two anterior pituitary hormones (following exclusion of sick euthyroid or sick eugonadal states). Isolated ACTH deficiency Isolated ACTH deficiency (IAD) is induced by PD-1 and PD

Article Type:
Review Article
Collections:
Hormones and Cancer
DOI:
https://doi.org/10.1530/EC-22-0513
Volume/Issue:
Volume 12: Issue 5
Open access
Daniel Alexander Hescheler Department of Nuclear Medicine, University Hospital Münster, Münster, Germany
European Institute for Molecular Imaging (EIMI), University of Münster, Münster, Germany

Search for other papers by Daniel Alexander Hescheler in
Google Scholar
PubMed Close
,
Milan Janis Michael Hartmann Department of General, Visceral, Tumor and Transplant Surgery, University Hospital Cologne, Cologne, Germany

Search for other papers by Milan Janis Michael Hartmann in
Google Scholar
PubMed Close
,
Burkhard Riemann Department of Nuclear Medicine, University Hospital Münster, Münster, Germany

Search for other papers by Burkhard Riemann in
Google Scholar
PubMed Close
,
Maximilian Michel Institute of Zoology, University of Cologne Germany, Cologne, Germany

Search for other papers by Maximilian Michel in
Google Scholar
PubMed Close
,
Christiane Josephine Bruns Department of General, Visceral, Tumor and Transplant Surgery, University Hospital Cologne, Cologne, Germany

Search for other papers by Christiane Josephine Bruns in
Google Scholar
PubMed Close
,
Hakan Alakus Department of General, Visceral, Tumor and Transplant Surgery, University Hospital Cologne, Cologne, Germany

Search for other papers by Hakan Alakus in
Google Scholar
PubMed Close
, and
Costanza Chiapponi Department of General, Visceral, Tumor and Transplant Surgery, University Hospital Cologne, Cologne, Germany

Search for other papers by Costanza Chiapponi in
Google Scholar
PubMed Close

therapies under investigation  Atezolizumab  Bevacizumab  Cobimetinib  Vemurafenib  Paclitaxel  Nab-Paclitaxel  NCT03181100 Atezolizumab: PD-1L Bevacizumab: VEGFR Cobimetinib: MEK1, MEK2 Vemurafenib: BRAF V600E Paclitaxel: antimicrotubule agent Nab

Article Type:
Research Article
Collections:
Hormones and Cancer
DOI:
https://doi.org/10.1530/EC-21-0624
Volume/Issue:
Volume 11: Issue 4
Open access
Vita Birzniece School of Medicine, Western Sydney University, New South Wales, Australia
Department of Diabetes and Endocrinology, Blacktown Hospital, New South Wales, Australia
Garvan Institute of Medical Research, New South Wales, Australia
School of Medical Sciences, University of New South Wales, New South Wales, Australia

Search for other papers by Vita Birzniece in
Google Scholar
PubMed Close
,
Teresa Lam School of Medicine, Western Sydney University, New South Wales, Australia
Department of Diabetes and Endocrinology, Blacktown Hospital, New South Wales, Australia
Department of Diabetes and Endocrinology, Westmead Hospital, New South Wales, Australia

Search for other papers by Teresa Lam in
Google Scholar
PubMed Close
,
Mark McLean School of Medicine, Western Sydney University, New South Wales, Australia
Department of Diabetes and Endocrinology, Blacktown Hospital, New South Wales, Australia

Search for other papers by Mark McLean in
Google Scholar
PubMed Close
,
Navneeta Reddy Department of Diabetes and Endocrinology, Blacktown Hospital, New South Wales, Australia

Search for other papers by Navneeta Reddy in
Google Scholar
PubMed Close
,
Haleh Shahidipour School of Medicine, Western Sydney University, New South Wales, Australia
Department of Diabetes and Endocrinology, Blacktown Hospital, New South Wales, Australia

Search for other papers by Haleh Shahidipour in
Google Scholar
PubMed Close
,
Amy Hayden School of Medicine, Western Sydney University, New South Wales, Australia
Faculty of Medicine, Health and Human Sciences, Macquarie University, New South Wales, Australia
Crown Princess Mary Cancer Centre, Westmead Hospital, New South Wales, Australia

Search for other papers by Amy Hayden in
Google Scholar
PubMed Close
,
Howard Gurney Crown Princess Mary Cancer Centre, Westmead Hospital, New South Wales, Australia

Search for other papers by Howard Gurney in
Google Scholar
PubMed Close
,
Glenn Stone School of Computing, Engineering and Mathematics, Western Sydney University, New South Wales, Australia

Search for other papers by Glenn Stone in
Google Scholar
PubMed Close
,
Rikke Hjortebjerg Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
Endocrine Research Unit, Department of Endocrinology, Odense University Hospital & Department of Clinical Research, Faculty of Health, University of Southern Denmark, Odense, Denmark
Steno Diabetes Center Odense, Odense University Hospital & Department of Clinical Research, Faculty of Health, University of Southern Denmark, Odense, Denmark

Search for other papers by Rikke Hjortebjerg in
Google Scholar
PubMed Close
, and
Jan Frystyk Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
Endocrine Research Unit, Department of Endocrinology, Odense University Hospital & Department of Clinical Research, Faculty of Health, University of Southern Denmark, Odense, Denmark

Search for other papers by Jan Frystyk in
Google Scholar
PubMed Close

hypogonadism, it is associated with the development of obesity, insulin resistance, hyperinsulinemia, and increased cardiovascular disease risk ( 1 , 2 ). The metabolic syndrome is present in >50% of men receiving long-term ADT compared to 20% of matched

Article Type:
Research Article
Collections:
Hormones and Cancer
DOI:
https://doi.org/10.1530/EC-21-0375
Volume/Issue:
Volume 11: Issue 4
Open access
Nikolaos Kyriakakis Department of Endocrinology, Leeds Centre for Diabetes & Endocrinology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
Leeds Institute for Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK

Search for other papers by Nikolaos Kyriakakis in
Google Scholar
PubMed Close
,
Marilena Giannoudi Department of Endocrinology, Leeds Centre for Diabetes & Endocrinology, Leeds Teaching Hospitals NHS Trust, Leeds, UK

Search for other papers by Marilena Giannoudi in
Google Scholar
PubMed Close
,
Satish S Kumar Department of Endocrinology, Leeds Centre for Diabetes & Endocrinology, Leeds Teaching Hospitals NHS Trust, Leeds, UK

Search for other papers by Satish S Kumar in
Google Scholar
PubMed Close
,
Khyatisha Seejore Department of Endocrinology, Leeds Centre for Diabetes & Endocrinology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
Leeds Institute for Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK

Search for other papers by Khyatisha Seejore in
Google Scholar
PubMed Close
,
Georgios K Dimitriadis Department of Endocrinology, King’s College Hospital NHS Foundation Trust, Denmark Hill, London, UK

Search for other papers by Georgios K Dimitriadis in
Google Scholar
PubMed Close
,
Harpal Randeva Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK

Search for other papers by Harpal Randeva in
Google Scholar
PubMed Close
,
Adam Glaser Pediatric Oncology, Leeds General Infirmary, Leeds Teaching Hospitals NHS Trust, Leeds, UK
Leeds Institute of Medical Research, University of Leeds, UK

Search for other papers by Adam Glaser in
Google Scholar
PubMed Close
,
Michelle Kwok-Williams Clinical Oncology, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK

Search for other papers by Michelle Kwok-Williams in
Google Scholar
PubMed Close
,
Georgina Gerrard Clinical Oncology, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK

Search for other papers by Georgina Gerrard in
Google Scholar
PubMed Close
,
Carmel Loughrey Clinical Oncology, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK

Search for other papers by Carmel Loughrey in
Google Scholar
PubMed Close
,
Ahmed Al-Qaissi Department of Endocrinology, Leeds Centre for Diabetes & Endocrinology, Leeds Teaching Hospitals NHS Trust, Leeds, UK

Search for other papers by Ahmed Al-Qaissi in
Google Scholar
PubMed Close
,
Ramzi Ajjan Leeds Institute for Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK

Search for other papers by Ramzi Ajjan in
Google Scholar
PubMed Close
,
Julie Lynch Department of Endocrinology, Leeds Centre for Diabetes & Endocrinology, Leeds Teaching Hospitals NHS Trust, Leeds, UK

Search for other papers by Julie Lynch in
Google Scholar
PubMed Close
, and
Robert D Murray Department of Endocrinology, Leeds Centre for Diabetes & Endocrinology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
Leeds Institute for Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK

Search for other papers by Robert D Murray in
Google Scholar
PubMed Close

malignant brain tumours before the age of 15 years ( 1 ). Not dissimilar outcomes are observed in teenage and young adults (15–40 years), in whom 5-year survival approaches 68%. In contrast, considerably lower 5-year survival rates of up to 20% are observed

Article Type:
Research Article
Collections:
Hormones and Cancer
DOI:
https://doi.org/10.1530/EC-22-0491
Volume/Issue:
Volume 12: Issue 8
Open access
Malgorzata Fuksiewicz Laboratory of Tumor Markers, Department of Pathology and Laboratory Diagnostics, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

Search for other papers by Malgorzata Fuksiewicz in
Google Scholar
PubMed Close
,
Maria Kowalska Laboratory of Tumor Markers, Department of Pathology and Laboratory Diagnostics, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

Search for other papers by Maria Kowalska in
Google Scholar
PubMed Close
,
Agnieszka Kolasinska-Cwikla Department of Oncology and Radiotherapy, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

Search for other papers by Agnieszka Kolasinska-Cwikla in
Google Scholar
PubMed Close
, and
Beata Kotowicz Laboratory of Tumor Markers, Department of Pathology and Laboratory Diagnostics, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

Search for other papers by Beata Kotowicz in
Google Scholar
PubMed Close

patients and progression (PD) in 49 patients. In the study group, NSE levels were determined in 96 patients during treatment monitoring at 3 months and at 6 months after the first follow-up. The characteristics of the study group are presented in Table 1

Article Type:
Research Article
Collections:
Hormones and Cancer
DOI:
https://doi.org/10.1530/EC-21-0647
Volume/Issue:
Volume 11: Issue 9
Open access
Anela Blažević Department of Internal Medicine, Section Endocrinology, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, Netherlands

Search for other papers by Anela Blažević in
Google Scholar
PubMed Close
,
Anand M Iyer Department of Internal Medicine, Section Endocrinology, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, Netherlands

Search for other papers by Anand M Iyer in
Google Scholar
PubMed Close
,
Marie-Louise F van Velthuysen Department of Pathology, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, Netherlands

Search for other papers by Marie-Louise F van Velthuysen in
Google Scholar
PubMed Close
,
Johannes Hofland Department of Internal Medicine, Section Endocrinology, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, Netherlands

Search for other papers by Johannes Hofland in
Google Scholar
PubMed Close
,
Peter M van Koestveld Department of Internal Medicine, Section Endocrinology, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, Netherlands

Search for other papers by Peter M van Koestveld in
Google Scholar
PubMed Close
,
Gaston J H Franssen Department of Surgery, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, Netherlands

Search for other papers by Gaston J H Franssen in
Google Scholar
PubMed Close
,
Richard A Feelders Department of Internal Medicine, Section Endocrinology, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, Netherlands

Search for other papers by Richard A Feelders in
Google Scholar
PubMed Close
,
Marina Zajec Laboratory of Neuro-Oncology/Clinical & Cancer Proteomics, Department of Neurology, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, Netherlands

Search for other papers by Marina Zajec in
Google Scholar
PubMed Close
,
Theo M Luider Laboratory of Neuro-Oncology/Clinical & Cancer Proteomics, Department of Neurology, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, Netherlands

Search for other papers by Theo M Luider in
Google Scholar
PubMed Close
,
Wouter W de Herder Department of Internal Medicine, Section Endocrinology, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, Netherlands

Search for other papers by Wouter W de Herder in
Google Scholar
PubMed Close
, and
Leo J Hofland Department of Internal Medicine, Section Endocrinology, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, Netherlands

Search for other papers by Leo J Hofland in
Google Scholar
PubMed Close

effect was enhanced when MAOI was used in combination with immune checkpoint anti-PD-1 treatment ( 24 ). Also, MAO-A promotes tumor-associated macrophages’ immunosuppressive functions via upregulation of oxidative stress which could be regulated by the

Article Type:
Research Article
Collections:
Hormones and Cancer
DOI:
https://doi.org/10.1530/EC-22-0020
Volume/Issue:
Volume 11: Issue 4
Open access